tiprankstipranks
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
US Market
Holding VRDN?
Track your performance easily

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

1,369 Followers
See the Price Targets and Ratings of:

VRDN Analyst Ratings

Strong Buy
15Ratings
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Viridian
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$41.00
▲(140.33% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $41.00 with a high forecast of $61.00 and a low forecast of $27.00. The average price target represents a 140.33% change from the last price of $17.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","23":"$23","36":"$36","49":"$49","62":"$62"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,23,36,49,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.17,22.38769230769231,25.605384615384615,28.823076923076925,32.04076923076923,35.25846153846154,38.47615384615385,41.69384615384615,44.91153846153846,48.12923076923077,51.346923076923076,54.56461538461539,57.7823076923077,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.17,20.849230769230772,22.52846153846154,24.20769230769231,25.88692307692308,27.566153846153846,29.245384615384616,30.924615384615386,32.603846153846156,34.28307692307692,35.96230769230769,37.64153846153846,39.32076923076923,{"y":41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.17,19.772307692307695,20.374615384615385,20.97692307692308,21.57923076923077,22.181538461538462,22.783846153846156,23.386153846153846,23.98846153846154,24.590769230769233,25.193076923076923,25.795384615384616,26.39769230769231,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.35,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.21,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$61.00Average Price Target$41.00Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$61
Buy
257.56%
Upside
Reiterated
12/16/24
Promising Clinical Data and Strategic Advances Propel Buy Rating for Viridian Therapeutics
TD Cowen
Buy
Reiterated
12/16/24
TD Cowen Remains a Buy on Viridian Therapeutics (VRDN)
JMP Securities
$40$42
Buy
146.19%
Upside
Reiterated
12/16/24
Viridian Therapeutics' Veligrotug Shows Best-in-Class Potential in Phase 3 THRIVE-2 Trial for Chronic TED
Goldman Sachs
$31$35
Buy
105.16%
Upside
Reiterated
11/13/24
Viridian Therapeutic (VRDN) PT Raised to $35 at Goldman SachsGoldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $35.00 (from $31.00) while maintaining a Buy rating.
Jefferies
$45
Buy
163.77%
Upside
Assigned
11/13/24
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)

Best Analysts Covering Viridian Therapeutics

Which Analyst Should I Follow If I Want to Buy VRDN and Sell After:
1 Month
xxx
Success Rate
13/27 ratings generated profit
48%
Average Return
+4.56%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 48.15% of your transactions generating a profit, with an average return of +4.56% per trade.
3 Months
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
+3.60%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +3.60% per trade.
1 Year
Success Rate
19/38 ratings generated profit
50%
Average Return
+1.80%
reiterated a buy rating 12 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.80% per trade.
2 Years
xxx
Success Rate
17/38 ratings generated profit
45%
Average Return
+3.61%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 44.74% of your transactions generating a profit, with an average return of +3.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Strong Buy
36
32
31
28
29
Buy
4
4
5
4
5
Hold
2
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
38
37
33
35
In the current month, VRDN has received 34 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is $41.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

VRDN Financial Forecast

VRDN Earnings Forecast

The previous quarter’s earnings for VRDN were -$1.15.
The previous quarter’s earnings for VRDN were -$1.15.

VRDN Sales Forecast

The previous quarter’s earnings for VRDN were $86.00K.
The previous quarter’s earnings for VRDN were $86.00K.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is $41.00.
    What is VRDN’s upside potential, based on the analysts’ average price target?
    Viridian Therapeutics has 140.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRDN a Buy, Sell or Hold?
          Viridian Therapeutics has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Viridian Therapeutics’s price target?
            The average price target for Viridian Therapeutics is $41.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $61.00 ,the lowest forecast is $27.00. The average price target represents 140.33% Increase from the current price of $17.06.
              What do analysts say about Viridian Therapeutics?
              Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of VRDN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis